News
ARWR
28.70
+3.09%
0.86
Weekly Report: what happened at ARWR last week (0318-0322)?
Weekly Report · 2d ago
Friday 3/22 Insider Buying Report: DCTH, ARWR
NASDAQ · 5d ago
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
Weekly Report: what happened at ARWR last week (0311-0315)?
Weekly Report · 03/18 09:12
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
FDA approves Madrigal Pharmaceuticals' new drug for nonalcoholic steatohepatitis. Rezdiffra is the first U.S.-approved therapy for NASH. B. Riley upgrades the company's stock to Neutral from Sell. The company's shares are up 26% in the premarket.
Seeking Alpha · 03/15 12:19
Madrigal granted FDA approval for NASH therapy
Madrigal Pharmaceuticals' lead asset resmetirom is the first U.S.-approved therapy for a liver condition called nonalcoholic steatohepatitis. The drug will be indicated with diet and exercise for NASH with moderate to advanced liver fibrosis. Madrigal granted FDA approval for NASh therapy for March 14, 2024.
Seeking Alpha · 03/14 19:45
Noteworthy Thursday Option Activity: ARWR, RBLX, MRNA
NASDAQ · 03/14 19:20
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy. Companies focused on developing drugs for a liver disease called nonalcoholic steatohepatitis are among the notable decliners. Madrigal Pharmaceuticals' lead asset, resmetirom, is targeted at NASH.
Seeking Alpha · 03/14 14:42
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR)
TipRanks · 03/14 10:40
Liver drug developers outperform as U.S. awaits first NASH drug
Liver drug developers outperform as U.S. Awaits first NASH drug approval. Madrigal Pharmaceuticals awaits FDA clearance for its lead asset resmetirom. The company's shares have soared 16% this year, outperforming the biopharma industry.
Seeking Alpha · 03/13 17:29
Ionis stock jumps as MASH drug succeeds in mid-stage trial
Ionis Pharmaceuticals stock jumps as MASH drug succeeds in mid-stage trial of its investigational drug to treat a type of fatty liver disease. Shares of Ionis Pharmaceuticals (IONS) jumped 7% premarket. The drug met primary endpoint in a Phase 2 study.
Seeking Alpha · 03/13 12:00
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. Stocks were lower on Monday, with the Dow Jones index falling more than 150 points. Shares of EQT Corporation fell sharply after the company announced a merger agreement to acquire Equitrans Midstream. Ventyx Biosciences, Inc. Shares tumbled 18.5% to $8.09.
Benzinga · 03/11 14:37
Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals
Kenneth Myszkowski, the Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. Recently sold shares for US$1.4m. The sale of shares was at around the current price of US$35.19. In the last year Arrowhead pharmaceuticals insiders didn't buy any shares in the company. The company has a 4.0% of the company, but there is no insider buying in the last 12 months. It's better to look at the insider transactions of a company rather than its share price. Simply Wall St looks at Arrowhead Pharmas and finds 3 warning signs for shareholders.
Simply Wall St · 03/11 10:54
Weekly Report: what happened at ARWR last week (0304-0308)?
Weekly Report · 03/11 09:12
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Arrowhead Pharmaceuticals, Inc. Has reduced its earnings per share by 24% a year over the past three years. CEO Chris Anzalone's total compensation is 51% higher than the average for the industry. The company's total shareholder return over three years is 54% and shareholders will have a chance to vote at its AGM on 14th of March. Arrowhead pharmaceuticals has a CEO pay of US$9.9m for the year to 2023.
Simply Wall St · 03/08 19:25
Arrowhead Pharmaceutical Gains Over Initiation Of Phase 1/2a Study Of ARO-DM1
NASDAQ · 03/08 15:50
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Arrowhead Pharmaceuticals, Inc. Has dosed the first subjects in a Phase 1/2a study to evaluate ARO-DM1 in up to 48 subjects with type 1 myotonic dystrophy. The company's investigational RNA interference therapeutic is designed to reduce expression of a gene in the muscle.
Barchart · 03/08 06:30
Weekly Report: what happened at ARWR last week (0226-0301)?
Weekly Report · 03/04 09:12
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
Arrowhead Pharmaceuticals, Inc. Is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them.
Barchart · 03/04 06:30
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
The Cooper Companies, Inc. Shares rose 7.4% to $100.61 on Friday. The company reported better-than-expected first-quarter financial results and raised guidance. Dell Technologies Inc. (Dell) jumped 26.3% after reporting better- than-expected fourth-quarter results. The Nasdaq Composite gained around 0.5% in today's session.
Benzinga · 03/01 16:18
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.